Samsrita Labs Ltd
Incorporated in 1996, Samsarita Labs Ltd is
in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
- Market Cap ₹ 42.0 Cr.
- Current Price ₹ 18.5
- High / Low ₹ 32.4 / 12.2
- Stock P/E
- Book Value ₹ 8.08
- Dividend Yield 0.00 %
- ROCE -1.80 %
- ROE -2.31 %
- Face Value ₹ 10.0
Pros
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -17.9%
- Promoter holding is low: 31.4%
- Company has a low return on equity of -3.34% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| 1.28 | 0.58 | 1.90 | 1.43 | 0.01 | 0.02 | 0.02 | 0.00 | 0.00 | |
| 1.86 | 1.71 | 4.34 | 3.62 | 0.92 | 0.43 | 1.01 | 0.25 | 0.26 | |
| Operating Profit | -0.58 | -1.13 | -2.44 | -2.19 | -0.91 | -0.41 | -0.99 | -0.25 | -0.26 |
| OPM % | -45.31% | -194.83% | -128.42% | -153.15% | -9,100.00% | -2,050.00% | -4,950.00% | ||
| 0.01 | 0.03 | 0.11 | 0.16 | 0.15 | 1.91 | 0.29 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.01 | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.58 | -1.11 | -2.36 | -2.06 | -0.77 | 1.49 | -0.70 | -0.25 | -0.26 |
| Tax % | 124.14% | -5.41% | -1.27% | -3.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| -1.31 | -1.05 | -2.33 | -1.98 | -0.77 | 1.49 | -0.71 | -0.26 | -0.28 | |
| EPS in Rs | -1.28 | -0.89 | -1.69 | -1.34 | -0.52 | 1.01 | -0.48 | -0.18 | -0.19 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | % |
| TTM: | -8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -20% |
| 3 Years: | -11% |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -3% |
| Last Year: | -2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.26 | 11.76 | 13.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 | 14.81 |
| Reserves | -2.39 | -0.40 | -1.61 | -3.03 | -3.66 | -1.58 | -2.29 | -2.55 | -2.84 |
| 6.50 | 6.81 | 7.92 | 8.58 | 2.34 | 2.74 | 2.08 | 2.20 | 2.43 | |
| 4.88 | 4.73 | 6.11 | 7.85 | 3.09 | 1.16 | 0.96 | 1.09 | 1.17 | |
| Total Liabilities | 19.25 | 22.90 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 | 15.57 |
| 0.46 | 0.36 | 0.26 | 0.13 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | |
| CWIP | 14.85 | 16.13 | 17.77 | 18.99 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 4.22 | 4.80 | 4.80 | 4.79 | 4.76 |
| 3.93 | 6.40 | 8.19 | 9.08 | 9.08 | 9.06 | 7.49 | 7.49 | 7.55 | |
| Total Assets | 19.25 | 22.90 | 26.23 | 28.21 | 16.58 | 17.13 | 15.56 | 15.55 | 15.57 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -0.26 | -3.32 | -2.96 | -1.05 | -0.34 | -0.40 | 0.66 | -0.13 | -0.23 | |
| -1.09 | -1.19 | -1.55 | -1.11 | -0.23 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 1.27 | 4.83 | 4.19 | 2.17 | 0.55 | 0.40 | -0.67 | 0.13 | 0.22 | |
| Net Cash Flow | -0.08 | 0.32 | -0.32 | 0.01 | -0.02 | 0.01 | 0.00 | 0.00 | 0.00 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 932.46 | 1,806.12 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | ||
| Inventory Days | 0.00 | 0.00 | 0.00 | ||||||
| Days Payable | |||||||||
| Cash Conversion Cycle | 932.46 | 1,806.12 | 424.55 | 556.43 | 78,110.00 | 38,690.00 | 38,325.00 | ||
| Working Capital Days | -1,114.96 | -2,259.22 | -787.63 | -1,462.55 | 60,590.00 | 58,765.00 | 46,172.50 | ||
| ROCE % | -5.44% | -10.11% | -8.45% | -4.07% | 10.12% | -4.58% | -1.72% | -1.80% |
Documents
Announcements
-
Appointment of Company Secretary and Compliance Officer
1d - Mrs. M. Gita Usha Rani appointed Company Secretary and Compliance Officer effective 08.09.2025; 8+ years experience.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 08.09.2025
1d - Mrs. M. Gita Usha Rani appointed Company Secretary & Compliance Officer effective 08.09.2025.
-
Board Meeting Intimation for Board Meeting Schedule To Be Held On 8Th September, 2025
1 Sep - Board meeting on 08-09-2025 to appoint Mrs. M. Gita usha Rani as Company Secretary and Compliance Officer.
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
25 Aug - 29th AGM (25.08.2025): FY2024-25 financials adopted; directors appointed; total votes 8,162,125.
- Shareholder Meeting / Postal Ballot-Outcome of AGM 25 Aug
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Products & Services:[1][2]
a) Stem Cell R&D:
Stem Cell Research & Therapy,
Regenerative Medicine, Bio-artificial
organ scaffolds development, nano-biotechnology, Nano-formulation of
cancer Drugs, Molecular genetics,
and Molecular virology, Stem cell
and Cord blood banking
b) New Drug Discovery:
Wilson’s disease, Non-Alcoholic Steatohepatitis (NASH), Neuropathic Pain, Cardiovascular Diseases, Cystinosis, Huntington’s disease
c) RNA Interference:
For developing a new panel of miRNAs
as a novel Bio Marker
d) Medical Devices:
Extra-corporeal liver support devices, Bioengineering implantable humanized nerve conduits, implantable nanochips carrying insulin-producing cells, extra-corporeal devices, etc.
e) Molecular Diagnostics:
DNA, RNA, and chromosomal based tests
and Pre-natal and pre-implantation genetic diagnostics, etc.
f) Contract Research Organization:
Synthetic Chemistry, Medicinal Chemistry, Drug Development, API’s process research, scale-up activity, Natural products research, and Analytical services